Insider Selling: Stemline Therapeutics Inc (STML) COO Sells 14,040 Shares of Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 14,040 shares of Stemline Therapeutics stock in a transaction on Monday, January 8th. The shares were sold at an average price of $13.93, for a total transaction of $195,577.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74.
  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total transaction of $169,918.94.

Stemline Therapeutics Inc (NASDAQ STML) remained flat at $$15.85 during trading on Friday. 356,867 shares of the stock were exchanged, compared to its average volume of 333,311. The stock has a market capitalization of $400.80, a price-to-earnings ratio of -6.17 and a beta of -0.02. Stemline Therapeutics Inc has a 1 year low of $5.80 and a 1 year high of $17.40.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities analysts predict that Stemline Therapeutics Inc will post -2.68 earnings per share for the current fiscal year.

STML has been the subject of several research analyst reports. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a research report on Friday, November 10th. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $33.75.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Stemline Therapeutics by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after acquiring an additional 38,615 shares during the period. AXA lifted its stake in shares of Stemline Therapeutics by 44.9% in the 2nd quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after acquiring an additional 195,022 shares during the period. Lyon Street Capital LLC lifted its stake in shares of Stemline Therapeutics by 331.1% in the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after acquiring an additional 415,867 shares during the period. State Street Corp lifted its stake in shares of Stemline Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock worth $3,179,000 after acquiring an additional 35,116 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Stemline Therapeutics by 18.0% in the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after acquiring an additional 41,898 shares during the period. 50.27% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/05/stemline-therapeutics-inc-stml-coo-kenneth-hoberman-sells-14040-shares-of-stock.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply